Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2021-09-15 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2021-09-15 English
Rapport Financier Semestriel 30 juin 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 30 JUIN 2021' (Half-Year Financial Report as of June 30, 2021) for Innate Pharma S.A. It contains comprehensive financial statements, including the consolidated statement of financial position, income statement, cash flow statement, and notes to the financial statements, as well as a management report on activities. It is a full interim report, not an announcement or a summary, and it contains substantive financial data. H1 2021
2021-09-15 French
Innate Pharma reports first half 2021 financial results and business update
Earnings Release Classification · 95% confidence The document is a press release from Innate Pharma reporting its financial results for the six months ended June 30, 2021. It includes a summary of financial highlights, a table of consolidated financial statements (IFRS), and business/pipeline updates. While it contains financial data, it is structured as an earnings release announcement rather than a full, standalone interim report document. According to the filing definitions, this fits the 'Earnings Release' category. H1 2021
2021-09-15 English
FORM 6-K
Foreign Filer Report
2021-09-07 English
Innate Pharma Organise une Conférence Téléphonique et un Webcast pour ses Résultats Financiers au Premier Semestre 2021
Regulatory Filings Classification · 99% confidence The document is titled "INNATE PHARMA ORGANISE UNE CONFÉRENCE TÉLÉPHONIQUE ET UN WEBCAST POUR SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2021" (Innate Pharma organizes a conference call and webcast for its first-half 2021 financial results). It explicitly announces the date, time, and details for an upcoming conference call to discuss H1 2021 financial results. This is a classic announcement preceding the release of detailed financial results or a call transcript. Since it is an announcement about an event where financial results will be discussed, and it is not the full report itself (like 10-K or IR), it most closely aligns with an Earnings Release (ER) announcement, which typically precedes or coincides with the call detailing the results. However, the document itself is purely an invitation/announcement for the call, not the summary of the results (ER) nor the transcript (CT). Given the options, an announcement about a call to discuss financial results is often categorized as an Earnings Release (ER) announcement, or if it were shorter and just announcing the *publication* of the results document, it would be RPA. Since it details the *event* (conference call) for discussing the results, ER is the most appropriate fit among the financial reporting categories, as it pertains directly to the earnings event.
2021-09-07 French
Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update
Call Transcript Classification · 95% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST HALF 2021 BUSINESS UPDATE". It explicitly states the purpose is to announce a conference call scheduled for September 15, 2021, to discuss business progress during the first half of 2021. This structure—announcing a call to discuss results or updates—is characteristic of an Earnings Release (ER) or a Call Transcript (CT) announcement. Since the text is the announcement *of* the call, not the transcript itself, and it relates to periodic financial updates (First Half 2021), it aligns best with an Earnings Release (ER) announcement, which often precedes or coincides with the call where detailed results are discussed. However, the primary focus is the *event* (the conference call) itself, which is a strong indicator for Call Transcript (CT) if the transcript were present, or the announcement leading up to it. Given the options, an announcement about a conference call to discuss business updates (which usually include financial highlights) is often categorized alongside Earnings Releases (ER). Since the document is an announcement *about* a call, and not the call transcript itself, ER is a strong candidate if the call is primarily for earnings review. If the document were purely about scheduling the call without mentioning the financial update context, it might lean towards RNS. Since it explicitly mentions a 'business update' for the 'first half 2021', it is strongly related to periodic financial reporting. In many databases, the announcement of the earnings call is grouped with the Earnings Release (ER). I will classify it as ER because the call's purpose is a 'business update' for a specific financial period (H1 2021).
2021-09-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.